Annual SG&A
$6.10 M
-$4.18 M-40.67%
31 December 2023
Summary:
Qualigen Therapeutics annual selling, general & administrative expenses is currently $6.10 million, with the most recent change of -$4.18 million (-40.67%) on 31 December 2023. During the last 3 years, it has fallen by -$1.32 million (-17.77%). QLGN annual SG&A is now -50.31% below its all-time high of $12.27 million, reached on 31 December 2021.QLGN Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$1.15 M
+$158.70 K+16.09%
30 September 2024
Summary:
Qualigen Therapeutics quarterly selling, general & administrative expenses is currently $1.15 million, with the most recent change of +$158.70 thousand (+16.09%) on 30 September 2024. Over the past year, it has dropped by -$191.60 thousand (-14.33%). QLGN quarterly SG&A is now -65.12% below its all-time high of $3.28 million, reached on 31 December 2021.QLGN Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$478.25 M
-$7.85 M-1.67%
30 September 2024
Summary:
Qualigen Therapeutics TTM selling, general & administrative expenses is currently -$478.25 million, with the most recent change of -$7.85 million (-1.67%) on 30 September 2024. Over the past year, it has dropped by -$485.96 million (-6309.73%). QLGN TTM SG&A is now -625.95% below its all-time high of $12.29 million, reached on 31 March 2022.QLGN TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
QLGN Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -40.7% | -14.3% | -6309.7% |
| 3 y3 years | -17.8% | -60.3% | -5423.1% |
| 5 y5 years | - | +313.1% | -10000.0% |
QLGN Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -50.3% | at low | -65.1% | +18.9% | -112.5% | at low |
| 5 y | 5 years | -50.3% | at low | -65.1% | +313.1% | -626.0% | at low |
| alltime | all time | -50.3% | at low | -65.1% | +313.1% | -626.0% | at low |
Qualigen Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $1.15 M(+16.1%) | $4.15 M(-4.4%) |
| June 2024 | - | $986.50 K(-6.7%) | $4.34 M(-24.9%) |
| Mar 2024 | - | $1.06 M(+9.8%) | $5.78 M(-5.1%) |
| Dec 2023 | $6.10 M(-40.7%) | $962.80 K(-28.0%) | $6.10 M(-20.9%) |
| Sept 2023 | - | $1.34 M(-44.9%) | $7.70 M(-13.5%) |
| June 2023 | - | $2.43 M(+77.3%) | $8.90 M(-5.7%) |
| Mar 2023 | - | $1.37 M(-46.7%) | $9.44 M(-15.0%) |
| Dec 2022 | $10.27 M | $2.57 M(+1.2%) | $11.11 M(-6.0%) |
| Sept 2022 | - | $2.54 M(-14.4%) | $11.83 M(-2.9%) |
| June 2022 | - | $2.97 M(-2.3%) | $12.17 M(-1.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | $3.04 M(-7.5%) | $12.29 M(+0.2%) |
| Dec 2021 | $12.27 M(+65.5%) | $3.28 M(+13.7%) | $12.27 M(+36.5%) |
| Sept 2021 | - | $2.89 M(-6.5%) | $8.98 M(+1.4%) |
| June 2021 | - | $3.09 M(+2.6%) | $8.86 M(+13.0%) |
| Mar 2021 | - | $3.01 M(+9.0%) | $7.84 M(+62.3%) |
| Dec 2020 | $7.41 M | - | - |
| Sept 2020 | - | $2.76 M(+33.6%) | $4.83 M(+106.0%) |
| June 2020 | - | $2.07 M(+646.2%) | $2.35 M(+261.7%) |
| Sept 2019 | - | $277.20 K(-25.4%) | $648.60 K(+74.6%) |
| June 2019 | - | $371.40 K | $371.40 K |
FAQ
- What is Qualigen Therapeutics annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Qualigen Therapeutics?
- What is Qualigen Therapeutics annual SG&A year-on-year change?
- What is Qualigen Therapeutics quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Qualigen Therapeutics?
- What is Qualigen Therapeutics quarterly SG&A year-on-year change?
- What is Qualigen Therapeutics TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Qualigen Therapeutics?
- What is Qualigen Therapeutics TTM SG&A year-on-year change?
What is Qualigen Therapeutics annual selling, general & administrative expenses?
The current annual SG&A of QLGN is $6.10 M
What is the all time high annual SG&A for Qualigen Therapeutics?
Qualigen Therapeutics all-time high annual selling, general & administrative expenses is $12.27 M
What is Qualigen Therapeutics annual SG&A year-on-year change?
Over the past year, QLGN annual selling, general & administrative expenses has changed by -$4.18 M (-40.67%)
What is Qualigen Therapeutics quarterly selling, general & administrative expenses?
The current quarterly SG&A of QLGN is $1.15 M
What is the all time high quarterly SG&A for Qualigen Therapeutics?
Qualigen Therapeutics all-time high quarterly selling, general & administrative expenses is $3.28 M
What is Qualigen Therapeutics quarterly SG&A year-on-year change?
Over the past year, QLGN quarterly selling, general & administrative expenses has changed by -$191.60 K (-14.33%)
What is Qualigen Therapeutics TTM selling, general & administrative expenses?
The current TTM SG&A of QLGN is -$478.25 M
What is the all time high TTM SG&A for Qualigen Therapeutics?
Qualigen Therapeutics all-time high TTM selling, general & administrative expenses is $12.29 M
What is Qualigen Therapeutics TTM SG&A year-on-year change?
Over the past year, QLGN TTM selling, general & administrative expenses has changed by -$485.96 M (-6309.73%)